Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically causes mild, cold-like symptoms in most adults but can be deadly for infants—during weeks 32–36 of pregnancy.

Maternal RSV vaccination enhances antibody transfer to newborns, with optimal transfer efficiency observed when given at least five weeks before delivery.

As of last year, RSV vaccination with Abrysvo has been recommended for pregnant women in the United States from 32 to 36 weeks gestation, at the end of the third trimester.

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially preterm babies and infants under six months old. The younger the child, the smaller their lungs,

RSV is a common cause of coughs and colds but can also lead to severe respiratory illness, especially in the most vulnerable. Doctors say vaccination is especially important for older adults, pregnant women,